- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02297542
Immune Response to High-Dose vs. Standard Dose Influenza Vaccine
July 31, 2018 updated by: Janet McElhaney, Health Sciences North Research Institute
This 5-year proposal is a randomized study of split-virus influenza vaccine (SVV) in a high-dose (HD) vs. standard-dose (SD) formulation in each of five influenza seasons to define the key determinants of vaccine-mediated protection against influenza and how these immunologic mediators may be enhanced by vaccination with a newly approved high-dose influenza vaccine in older people
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
85
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
Sudbury, Ontario, Canada, P3E 5J1
- Health Sciences North Research Institute
-
-
-
-
Connecticut
-
Farmington, Connecticut, United States, 06030
- Center on Aging, UConn Health
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Written informed consent provided by the participant
- Age 20-40 years old with no underlying chronic diseases or age ≥65 years old
- Willing to receive influenza vaccination
Older cohort has received their influenza vaccine for the previous influenza season
-
Exclusion Criteria:
- Immunosuppressive disorders or medications (including oral prednisone in doses >10 mg daily)
- Have not received influenza vaccination in the past or cannot be vaccinated due to previous severe reaction to influenza vaccine, egg, latex, or thimerosol allergies, or refusal of vaccination
- Participant has received a community available influenza vaccine for the approaching influenza season
Females who are pregnant at Visit 1 (a pregnancy test will be administered for all females of child-bearing potential)
-
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Flu Vaccine SD
Fluzone Standard Dose Influenza Vaccine
|
Other Names:
|
Active Comparator: Flu Vaccine HD
Fluzone High Dose Influenza Vaccine
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Influenza Cases
Time Frame: five years
|
Influenza surveillance includes weekly contact with study subjects to assess for any flu-like symptoms or acute respiratory infection (ARI), and include nasopharyngeal swabs (within 5 days of onset of symptoms) for polymerase chain reaction (PCR) detection of influenza virus and post-influenza season detection of an antibody response to influenza infection.
Routine screen for symptoms of ARI will also occur at the 4, 10 and 20 week visits when blood samples are collected.
Influenza illness will be documented by PCR detection of influenza during an IARI or seroconversion (4-fold rise in antibody titers) in association with an ARI.
ARI includes upper (coryza or sore throat) or lower (cough or shortness of breath) respiratory tract symptoms, or headache, malaise, myalgia or fever (> 99°F or 37.3°C orally or 100°F rectally) [41].
as physician visits, hospitalizations and deaths attributed to acute cardiopulmonary illness and will be tracked through the influenza season.
|
five years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Janet E McElhaney, MD, Health Sciences North Research Institute
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2014
Primary Completion (Anticipated)
December 1, 2019
Study Completion (Anticipated)
December 1, 2019
Study Registration Dates
First Submitted
November 3, 2014
First Submitted That Met QC Criteria
November 19, 2014
First Posted (Estimate)
November 21, 2014
Study Record Updates
Last Update Posted (Actual)
August 1, 2018
Last Update Submitted That Met QC Criteria
July 31, 2018
Last Verified
February 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NIH R01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Elderly Immune System
-
University of Mississippi Medical CenterCompletedElderly Immune SenescenceUnited States
-
Istanbul Medipol University HospitalCompletedElderly | Balance; Distorted | Plantar | Falling | SensitivityTurkey
-
University of FloridaKyowa Hakko Bio Co., Ltd.CompletedImprovement in Immune Cell Function in Elderly HumansUnited States
-
DSM Nutritional Products, Inc.CompletedFrail Elderly | Pre-frail ElderlyNetherlands
-
Maimonides Medical CenterCompletedElderly | Frail Elderly | Hospitalization | Geriatrics
-
University of ThessalyCompletedFunctionality, Falls, Elderly, Fall Prevention, Exercise Elderly, Assessment, Rehabilitation, Community-DwellingGreece
-
Hospital Israelita Albert EinsteinConselho Nacional de Desenvolvimento Científico e Tecnológico; Paulo de Tarso...Recruiting
-
Istanbul Medipol University HospitalCompleted
-
Seoul National University HospitalCompleted
-
Purdue UniversityCompleted
Clinical Trials on Flu Vaccine
-
PepTcell LimitedCompleted
-
University of Southern CaliforniaWithdrawnImmunosenescence
-
The Jackson LaboratoryNational Institute of Allergy and Infectious Diseases (NIAID); University of... and other collaboratorsRecruitingAging | Influenza Vaccine | Vaccine Response | Dendritic CellUnited States
-
Duke UniversityCenters for Disease Control and Prevention; Children's Hospital Medical Center...CompletedPregnancyUnited States
-
University of Texas at AustinUnknownDepression | HealthyUnited States
-
Fondazione Policlinico Universitario Agostino Gemelli...CompletedInfluenza Vaccine | Cost-Benefit AnalysisItaly
-
Health Sciences North Research InstituteNOAMA NORTHERN ONTARIO ACADEMIC MEDICINE ASSOCIATIONUnknown
-
Roswell Park Cancer InstituteCompletedAcute Myeloid Leukemia | Myelodysplastic SyndromeUnited States
-
Colby Pharmaceutical CompanyCompleted
-
Mahidol UniversityWorld Health Organization; The Government Pharmaceutical OrganizationCompletedInfluenza Due to Influenza A Virus Subtype H5N2Thailand